News - Licensing, Eisai

Filter

Current filters:

LicensingEisai

Popular Filters

Eisai expands deal with Biogen; re-files Fycompa with G-BA; news on Zebinix

Eisai expands deal with Biogen; re-files Fycompa with G-BA; news on Zebinix

12-05-2014

Japanese drug major Eisai has exercised its option to jointly develop and commercialize its clinical…

Biogen IdecEisaiFycompaGermanyItalyLicensingNeurologicalPharmaceuticalPricingRegulationZebinix

Otsuka acquires certain Dacogen and E7727 rights from Eisai

01-04-2014

Otsuka Pharmaceutical has reached an agreement with the US subsidiary of fellow Japanese drugmaker Eisai…

DacogenE7727EisaiLicensingOncologyOtsukaPharmaceutical

Eisai and Biogen Idec collaborate on Alzheimer’s disease treatments

Eisai and Biogen Idec collaborate on Alzheimer’s disease treatments

05-03-2014

US biotech firm Biogen Idec and Japanese drugmaker Eisai have entered into a collaboration to develop…

BAN2401BIIB037Biogen IdecBiotechnologyE2609EisaiLicensingNeurologicalResearch

Eisai takes over marketing authorization for Gliadel, and joins TB partnership

Eisai takes over marketing authorization for Gliadel, and joins TB partnership

25-11-2013

Japanese drug major Eisai (TYO: 4523) will become the Marketing Authorization Holder for the antineoplastic…

Antibiotics and Infectious diseasesAsia-PacificEisaiGliadelLicensingNobelpharmaOncologyPharmaceutical

Eisai expands marketing and supply agreement for Belviq worldwide

Eisai expands marketing and supply agreement for Belviq worldwide

08-11-2013

Japanese drug major Eisai (TYO: 4523) has expanded the marketing and supply agreement between its US…

Asia-PacificBelviqEisaiGastro-intestinalsLicensingPharmaceutical

Vifor gets certain rights to Helsinn's netupitant-palonosetron

16-05-2013

Privately-held Helsinn Healthcare and fellow Switzerland-based Vifor Pharma, part of the Galenica group…

EisaiEuropeGalenicaHelsinnLicensingnetupitantOncologypalonosetronPharmaceuticalVifor Pharma

Valeant Pharma buys US rights to Eisai's Targretin for $65 million upfront

21-02-2013

Canada's Valeant Pharmaceuticals International (TSX: VRX) says that it has acquired US rights for Targretin…

EisaiLicensingNorth AmericaOncologyPharmaceuticalTargretinValeant Pharmaceuticals

Santen in ophthalmics deal with Eisai; Sets up new company in China

26-09-2012

Japan's Santen Pharmaceutical (TYO: 4536) has entered into an option agreement with drug major Eisai…

Asia-PacificEisaiLicensingMarkets & MarketingOphthalmicsPharmaceuticalSanten Pharmaceuticals

Eisai enters deals with Valeant and Minophagen

04-04-2012

The European subsidiary of Japanese drug major Eisai (TYO: 4523) and PharmaSwiss, a division of Canada-based…

bexaroteneEisaiHalavenLicensingMarkets & MarketingMinophagenOncologyPharmaceuticalValeant Pharmaceuticals

Eisai in deal with Novartis to co-promote COPD drugs in Japan

21-11-2011

Japanese drugmaker Eisai (TYO: 4523) has entered into a Japan co-promotion agreement with the local subsidiary…

Asia-PacificEisaiLicensingMarkets & MarketingNovartisOnbrezPharmaceuticalRespiratory and Pulmonary

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top